US Patent

US9603853 — Formulations of viloxazine

Method of Use · Assigned to Supernus Pharmaceuticals Inc · Expires 2033-02-07 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent discloses modified release formulations of viloxazine hydrochloride and methods of administering them.

USPTO Abstract

Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.

Drugs covered by this patent

viloxazine-hydrochloride (VILOXAZINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-727`	—	viloxazine-hydrochloride
`U-727`	—	viloxazine-hydrochloride
`U-727`	—	viloxazine-hydrochloride

Patent Metadata

Patent number: US9603853
Jurisdiction: US
Classification: Method of Use
Expires: 2033-02-07
Drug substance claim: No
Drug product claim: No
Assignee: Supernus Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.